Cargando…

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 premenopausal patients (Asians, Middle Eastern Arabs, Cauc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saladores, P, Mürdter, T, Eccles, D, Chowbay, B, Zgheib, N K, Winter, S, Ganchev, B, Eccles, B, Gerty, S, Tfayli, A, Lim, J S L, Yap, Y S, Ng, R C H, Wong, N S, Dent, R, Habbal, M Z, Schaeffeler, E, Eichelbaum, M, Schroth, W, Schwab, M, Brauch, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308646/ https://www.ncbi.nlm.nih.gov/pubmed/25091503 http://dx.doi.org/10.1038/tpj.2014.34

Ejemplares similares

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes
por: Johänning, Janina, et al.
Publicado: (2017)

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
por: Li, Jingmei, et al.
Publicado: (2013)

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
por: Khalaj, Zahra, et al.
Publicado: (2019)

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
por: Nardin, Jeanine Marie, et al.
Publicado: (2019)

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
por: Kovar, Christina, et al.
Publicado: (2022)

High-grade ER-negative tumour breast cancers are characteristic of both very young onset cases and patients with hereditary breast cancer
por: Eccles, D, et al.
Publicado: (2006)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women
por: Eriksson, Mikael, et al.
Publicado: (2021)

Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study
por: Gerty, SM, et al.
Publicado: (2008)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Inactivation of the retinoblastoma tumour suppressor pathway in premenopausal breast cancer is associated with resistance to tamoxifen
por: Lehn, S, et al.
Publicado: (2009)

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
por: Lee, Maria, et al.
Publicado: (2020)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
por: Cohen, I., et al.
Publicado: (1994)

Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study
por: Copson, E, et al.
Publicado: (2014)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
por: Brennan, Donal J, et al.
Publicado: (2011)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study
por: Almeida, Thais, et al.
Publicado: (2022)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers
por: Yap, Yoon-Sim, et al.
Publicado: (2018)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

Birth characteristics of premenopausal women with breast cancer.
por: Le Marchand, L., et al.
Publicado: (1988)

Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
por: Ryu, Ki-Jin, et al.
Publicado: (2022)

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol
por: Eccles, Diana, et al.
Publicado: (2007)

The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer
por: Tapper, William, et al.
Publicado: (2008)

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
por: Lundgren, Katja, et al.
Publicado: (2008)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
por: Lundgren, Christine, et al.
Publicado: (2023)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study
por: Maishman, Tom, et al.
Publicado: (2017)

Understanding of BRCA VUS genetic results by breast cancer specialists
por: Eccles, B. K., et al.
Publicado: (2015)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1ojq7cclct75oakuk1o5gfcajc